A Randomized, Multi-center, Blinded, Placebo-controlled Study With an Openlabel Run-in Period to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daily, Single, Subcutaneous Injections of r-metHuiL-1ra (Anakinra) in Polyarticular-Course Juvenile Rheumatoid Arthritis
- Registry ID
- EUCTR2015-002466-22
- Source registry
- EUCTR
- Phase
- PHASE2
- Sponsor
- Amgen Inc
- Last update
- 2026-08-16
Conditions
- Juvenile Rheumatoid Arthritis
Summary
The primary objective of this study was to evaluate the safety of anakinra
View on source registry